期刊文献+

消化道肿瘤化疗及靶向治疗药物过敏反应的临床对策(附25例分析) 被引量:4

在线阅读 下载PDF
导出
摘要 目的评价消化道肿瘤常用化疗及靶向治疗药物奥沙利铂,紫杉醇及西妥昔单抗的过敏反应的临床表现及治疗策略。方法回顾性分析使用奥沙利铂,紫杉醇及西妥昔单抗发生过敏反应的病例,奥沙利铂组16例,紫杉醇组5例,西妥昔单抗组4例。结果奥沙利铂组发生过敏反应的中位周期数为第7周期,15例患者在开始输注90min内发生,1例患者发生在输注结束后。而紫杉醇和西妥昔单抗的过敏反应均发生在首次用药10min内,并且这3种药物的过敏反应的症状及临床治疗对策不同。结论奥沙利铂,紫杉醇及西妥昔单抗发生过敏发应的化疗周期数及其距开始输注药物时间各有特点,临床医生应根据其特点密切监测,并给予恰当的治疗。
出处 《临床药物治疗杂志》 2009年第5期57-60,共4页 Clinical Medication Journal
作者简介 通讯作者:eamil:zxd0829@yahoo.com.cn
  • 相关文献

参考文献17

  • 1Shepherd GM : Hypersensitivity reactions to chemotherapeuticdrugs. Clin Rev Allergy Immunol, 2003, 24: 253-262.
  • 2Maindrault -Goebel F, Andre T, Tournigand C, et al. Allergic -type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer, 2005, 41 (15) : 2262- 2267.
  • 3Tournigand C, Maindrault - Goebel F, Louver C, et al. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer, 1998, 34: 1297- 1298.
  • 4Andre T, Boni C, Mounedji - Boudiaf L, et al. Oxaliplatin fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med, 2004, 350:2343-2351.
  • 5Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 2003, 14 (3): 497-498.
  • 6Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxalipiatin and other antincoplastic agents. Curr Allergy Asthma Rep, 2008, 8 (1): 56- 62.
  • 7Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J cancer, 2003, 89 477- 481.
  • 8Bhargava P, Gammon D, McCormick M J, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 2004 100:211-212.
  • 9Alliot C, Messouak D, Beets C, et al. Severe anaphylactic reaction to oxaliplatin. Clin Oncol, 2001, 13:236.
  • 10Weiss RB, Donehower RC, Wernik PH, et al. Hypersensltivity reactions from Taxol. J Clin Oncol, 1990, 8: 1263- 1268.

同被引文献64

  • 1赵建琴,董玉华,高秀清.消化道恶性肿瘤时辰化疗患者的护理[J].护理学杂志,2005,20(5):21-23. 被引量:6
  • 2杜媛.个体化健康教育对改善消化道肿瘤化疗患者疲劳状况的研究[J].实用中医内科杂志,2006,20(1):14-15. 被引量:7
  • 3邵仲英,封宇飞,傅得兴.新型表皮生长因子受体抑制剂——西妥昔单抗[J].中国全科医学,2006,9(4):317-318. 被引量:12
  • 4陈勇,刘巍.Cetuximab研究现状[J].中国肿瘤临床,2006,33(23):1376-1379. 被引量:4
  • 5王洁.重组表皮因子受体抑制剂相关皮肤副反应.中国医学论坛报,2008,11(4):10-10.
  • 6Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic eolorectal cancer [ J]. N Engl J Med, 2004,351 (4) :337-345.
  • 7National Cancer Institute. Cancer therapy evaluation pro gram. CT-CAE v3. 0 [S/OL]. (2005-12-29) [2007-06-11]. http..//ctep, cancer, gov/reporting/ctc- v3. 0. ht ml.
  • 8Vallbohmer D, Zhang W, Gordon M, et al. Moleeular determinants of eetuximab effieaey[J]. J Clin Oneol, 2005,23(15) :3536-3544.
  • 9BLICK SK, SCOTT LJ. Cetuximab: a review of its use insquamous cell carcinoma of the head and neck and metastaticcolorectal cancer[J]. Drugs, 2007, 67(17) : 2585-2607.
  • 10MENDELSOHN J, BASELGA J. Status of epidermal growthfactor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003, 21(14): 2787-2799.

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部